<DOC>
	<DOCNO>NCT01768962</DOCNO>
	<brief_summary>To compare local systemic pharmacokinetics tenofovir reduced-glycerin 1 % gel 2 week daily rectal use 2 week daily vaginal use</brief_summary>
	<brief_title>Tenofovir Levels Following Local Application Tenofovir Reduced-Glycerin 1 % Gel</brief_title>
	<detailed_description />
	<mesh_term>Glycerol</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Age 21 45 year ( inclusive ) Screening 2 . Able willing provide write informed consent 3 . Able willing comply study procedure requirement , include , clinical laboratory assessment , vaginal rectal examination , urine blood testing , well attendance schedule study visit 4 . In general good health Screening Enrollment determine Investigator Record ( IoR ) / designee 5 . Negative pregnancy test Screening Enrollment 6 . HIVnegative Screening Enrollment 7 . Able willing provide adequate locator information 8 . Willingness use studyprovided male condom duration study participation penetrative intercourse 9 . Per participant report Screening , regular menstrual cycle least 21 day menses ( apply participant report use progestinonly method contraception screening , e.g. , DepoProvera , progesteronecontaining IUDs extend use oral contraceptive ) 10 . Per participant report Enrollment , use effective method contraception intend use effective method duration study participation ; effective method include : Hormonal method , exclude vaginal ring Intrauterine device ( IUD ) insert least 42 day prior Enrollment ( past maximum length recommend usage accord package instruction ) Sterilization participant partner least 42 day prior Enrollment Selfidentifies woman sex woman exclusively Sexually abstinent least 90 day prior enrollment intention remain sexually abstinent duration study participation 11 . Per participant report Screening , state willingness refrain insert nonstudy vaginal rectal product object vagina rectum , include limited , spermicide , female condom , diaphragm , contraceptive vaginal ring , vaginal medication , menstrual cup , cervical cap ( vaginal barrier method ) , vaginal/rectal douche , enema , nonstudy approve lubricant , sex toy ( vibrator , dildo , etc . ) , tampon duration study product use period 24 hour prior schedule study clinic visit . 12 . Pap result consistent Grade 0 accord Female Genital Grading Table Use Microbicide Studies Addendum 1 Division AIDS ( DAIDS ) Table Grading Severity Adult Pediatric Adverse Events , Version 1.0 , December 2004 ( Clarification date August 2009 ) satisfactory evaluation nonGrade 0 Pap result treatment require per clinical judgment IoR designee 12 calendar month prior Enrollment Visit 13 . At Screening , participant agrees take part research study involve drug , medical device , vaginal/rectal product duration study participation ( include time Screening Enrollment visit ) Participants biopsy subset must also meet follow criterion Screening eligible inclusion : 14 . Willing abstain insert anything vagina rectum 72 hour prior follow collection sample , include vaginal rectal intercourse 15 . Willing restrict use nonsteroidal antiinflammatory drug ( NSAIDs ) , aspirin and/or drug associate increase likelihood bleeding follow mucosal biopsy collection 72 hour prior follow collection biopsy 1 . Participant report follow : 1 . Known adverse reaction study product ( ever ) 2 . Known adverse reaction latex ( ever ) 3 . Current male sex partner know history adverse reaction latex ( ever ) 4 . History serum HBsAg positivity ( ever ) 5 . Nontherapeutic injection drug use 12 calendar month prior Enrollment 6 . STI reproductive tract infection ( RTI ) require treatment 6 calendar month prior Enrollment 7 . Postexposure prophylaxis ( PEP ) possible HIV1 infection within 6 calendar month prior Enrollment 8 . Last pregnancy outcome within 90 day less prior Enrollment 9 . Gynecologic genital procedure ( e.g. , tubal ligation , dilation curettage ) within 42 day prior Enrollment Note : This include biopsy evaluation abnormal pap result endometrial biopsy occur 7 day prior Enrollment , provide inclusion/exclusion criterion meet . 10 . Participation research study involve drug , medical device vaginal product 42 day less prior Enrollment 11 . Anticipated IUD replacement within next 3 month IUD insert 42 day less prior Enrollment 12 . Participant report Screening and/or Enrollment intention become pregnant next 3 month 13 . Currently breastfeed time Screening and/or Enrollment 14 . History bleed problem ( Participants biopsy subset ) 2 . Laboratory abnormality Screening great equal Grade 2* : 1 . Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) 2 . Hemoglobin 3 . Platelet count 4 . Serum creatinine Otherwise eligible participant exclusionary test result ( ) list may retested screen process . If participant retested nonexclusionary result document within 42 day provide informed consent , participant may enrol . 3 . Urinary tract infection ( UTI ) Screening and/or Enrollment Note : Otherwise eligible participant diagnose UTI Screening offer treatment may enrol complete treatment symptom resolve . If treatment complete symptom resolve within 42 day obtain informed consent , participant may enrol . 4 . Pelvic inflammatory disease STI RTI require treatment per current WHO guideline Screening and/or Enrollment 5 . Clinically apparent Grade 2 high pelvic** and/or rectal*** examination finding ( observe study staff ) Screening and/or Enrollment Note : Cervical bleeding associate speculum insertion and/or specimen collection judge within range normal accord clinical judgment IoR/designee consider expect nonmenstrual bleeding exclusionary . Note : Otherwise eligible participant exclusionary pelvic and/or rectal examination finding may enrolled/randomized finding improve nonexclusionary severity grade resolve . If improvement nonexclusionary grade resolution document within 42 day provide informed consent , participant may enrol . 6 . Any condition , opinion IoR/designee , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective per Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) ** per Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) , Addendum 1 Female Genital Grading Table Use Microbicide Studies *** per Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) , Addendum 3 Rectal Grading Table Use Microbicide Studies ( Clarification date May 2012 ) .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Microbicides</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>Reduced-glycerin</keyword>
	<keyword>Vaginal use</keyword>
	<keyword>Rectal use</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>